CAJ | 학술논문

吉西他滨联合化疗是治疗复发或转移性乳腺癌的有效方案。除了标准的联合紫杉醇3周方案之外，根据个体化治疗原则，也可选择不同的联合药物如多西他赛或铂类，或是采取不同的给药频率和剂量以及延长给药周期进行维持。吉西他滨联合紫杉类药物对于有内脏转移、激素受体阴性的患者临床获益更加明显，初步循证结果证明了后续进行同方案维持治疗的可行性。另外，吉西他滨联合顺铂方案是治疗转移性三阴乳腺癌更优的选择。
길서타빈연합화료시치료복발혹전이성유선암적유효방안。제료표준적연합자삼순3주방안지외，근거개체화치료원칙，야가선택불동적연합약물여다서타새혹박류，혹시채취불동적급약빈솔화제량이급연장급약주기진행유지。길서타빈연합자삼류약물대우유내장전이、격소수체음성적환자림상획익경가명현，초보순증결과증명료후속진행동방안유지치료적가행성。령외，길서타빈연합순박방안시치료전이성삼음유선암경우적선택。
Gemcitabine based chemotherapy is effective in recurrent or metastatic breast cancer. Besides the 3 week regimen in combination with paclitaxel,individualized treatments are also applied to com-bine gemcitabine with other agents such as docetaxel or platinum,or to administer by different frequency or dose,or to continuously maintain on the treatment as an extension to front line.It is demonstrated that gemci-tabine in combination with taxanes can obtain survival benefit,largely in patients with visceral metastasis or hor-mone receptor negative.Initial evidence has also supported the feasibility of continuous maintenance.Finally, gemci-tabine in combination with cisplatin is a better option for the metastatic triple negative breast cancer.